Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid

 April 13, 2026

Pharmaceutical Technology

AbbVie’s deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.

M&A / DealsPain & AnaesthesiaRead full story

Post navigation

FDA issues complete response letter to Replimune’s RP1 for melanoma →
← AbbVie enters world of pain in up to $715M deal with China’s Haisco

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com